Dr. Julia Schueler, therapeutic area lead oncology and research director at Charles River Laboratories in Freiburg, germany, brings cutting-edge preclinical and translational expertise to the EASYGEN consortium.Within the EASYGEN Consortium, Dr. Schüler and her team contribute to Work Packages 5, developing regulatory compliance strategy, and 7, next generation CAR-T treatment, developing a 3D in vitro testing platform for new cell therapy candidates.Their mission: to accelerate development, reduce reliance on animal testing, and help bring innovative cell therapies to patients faster than ever before.By combining scientific rigor with innovation, Charles River plays a key role in transforming cell and gene therapy research into clinical reality.Collaboration. Innovation. Access.That’s what EASYGEN — and its partners like Charles River — stand for.#EASYGEN #CART #3DModels #Innovation #TranslationalResearch